These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028 [TBL] [Abstract][Full Text] [Related]
5. Comparison of CSF neurofilament light chain, neurogranin, and tau to MRI markers. Mielke MM; Przybelski SA; Lesnick TG; Kern S; Zetterberg H; Blennow K; Knopman DS; Graff-Radford J; Petersen RC; Jack CR; Vemuri P Alzheimers Dement; 2021 May; 17(5):801-812. PubMed ID: 33663022 [TBL] [Abstract][Full Text] [Related]
6. Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus. Lukkarinen H; Tesseur I; Pemberton D; Van Der Ark P; Timmers M; Slemmon R; Janssens L; Streffer J; Van Nueten L; Bottelbergs A; Rauramaa T; Koivisto AM; Herukka SK; Korhonen VE; Junkkari A; Hiltunen M; Engelborghs S; Blennow K; Zetterberg H; Kolb HC; Leinonen V J Alzheimers Dis; 2021; 80(4):1629-1642. PubMed ID: 33720890 [TBL] [Abstract][Full Text] [Related]
7. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease. Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800 [TBL] [Abstract][Full Text] [Related]
8. Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease. Mattsson N; Andreasson U; Zetterberg H; Blennow K; JAMA Neurol; 2017 May; 74(5):557-566. PubMed ID: 28346578 [TBL] [Abstract][Full Text] [Related]
9. Associations of Neurodegeneration Biomarkers in Cerebrospinal Fluid with Markers of Alzheimer's Disease and Vascular Pathology. Shir D; Mielke MM; Hofrenning EI; Lesnick TG; Knopman DS; Petersen RC; Jack CR; Algeciras-Schimnich A; Vemuri P; Graff-Radford J J Alzheimers Dis; 2023; 92(3):887-898. PubMed ID: 36806507 [TBL] [Abstract][Full Text] [Related]
10. Subtle Differences in Cognition in 70-Year-Olds with Elevated Cerebrospinal Fluid Neurofilament Light and Neurogranin: A H70 Cross-Sectional Study. Rådestig MA; Skoog J; Zetterberg H; Skillbäck T; Zettergren A; Sterner TR; Fässberg MM; Sacuiu S; Waern M; Wetterberg H; Blennow K; Skoog I; Kern S J Alzheimers Dis; 2023; 91(1):291-303. PubMed ID: 36617786 [TBL] [Abstract][Full Text] [Related]
11. Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ Hampel H; Toschi N; Baldacci F; Zetterberg H; Blennow K; Kilimann I; Teipel SJ; Cavedo E; Melo Dos Santos A; Epelbaum S; Lamari F; Genthon R; Dubois B; Floris R; Garaci F; Lista S; Alzheimers Dement; 2018 Apr; 14(4):492-501. PubMed ID: 29328927 [TBL] [Abstract][Full Text] [Related]
12. CSF neurogranin as a neuronal damage marker in CJD: a comparative study with AD. Blennow K; Diaz-Lucena D; Zetterberg H; Villar-Pique A; Karch A; Vidal E; Hermann P; Schmitz M; Ferrer Abizanda I; Zerr I; Llorens F J Neurol Neurosurg Psychiatry; 2019 Aug; 90(8):846-853. PubMed ID: 31097472 [TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study. Abu-Rumeileh S; Mometto N; Bartoletti-Stella A; Polischi B; Oppi F; Poda R; Stanzani-Maserati M; Cortelli P; Liguori R; Capellari S; Parchi P J Alzheimers Dis; 2018; 66(2):551-563. PubMed ID: 30320576 [TBL] [Abstract][Full Text] [Related]
14. Comparison of variables associated with cerebrospinal fluid neurofilament, total-tau, and neurogranin. Mielke MM; Syrjanen JA; Blennow K; Zetterberg H; Skoog I; Vemuri P; Machulda MM; Graff-Radford J; Knopman DS; Jack CR; Petersen RC; Kern S Alzheimers Dement; 2019 Nov; 15(11):1437-1447. PubMed ID: 31668594 [TBL] [Abstract][Full Text] [Related]
15. Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment. Kern S; Syrjanen JA; Blennow K; Zetterberg H; Skoog I; Waern M; Hagen CE; van Harten AC; Knopman DS; Jack CR; Petersen RC; Mielke MM JAMA Neurol; 2019 Feb; 76(2):187-193. PubMed ID: 30419087 [TBL] [Abstract][Full Text] [Related]
16. A Review of Fluid Biomarkers for Alzheimer's Disease: Moving from CSF to Blood. Blennow K Neurol Ther; 2017 Jul; 6(Suppl 1):15-24. PubMed ID: 28733960 [TBL] [Abstract][Full Text] [Related]
18. Associations of longitudinal plasma p-tau181 and NfL with tau-PET, Aβ-PET and cognition. Rauchmann BS; Schneider-Axmann T; Perneczky R; J Neurol Neurosurg Psychiatry; 2021 Dec; 92(12):1289-1295. PubMed ID: 34187867 [TBL] [Abstract][Full Text] [Related]
19. P-tau and neurodegeneration mediate the effect of β-amyloid on cognition in non-demented elders. Ma LZ; Hu H; Wang ZT; Ou YN; Dong Q; Tan L; Yu JT Alzheimers Res Ther; 2021 Dec; 13(1):200. PubMed ID: 34911582 [TBL] [Abstract][Full Text] [Related]